标签归档：fmk

Z-WEHD-FMK

发表于由

Z-WEHD-FMK; 纯度: 98.64%

Z-WEHD-FMK 是一种强效具有细胞通透性可逆的 caspase-1/5 抑制剂。Z-WEHD-FMK 也抑制 cathepsin B 的活性 (IC50=6 μM)。Z-WEHD-FMK 可用于检测细胞凋亡。

Z-WEHD-FMKamp;;

Z-WEHD-FMK Chemical Structure

CAS No. : 210345-00-9

规格 价格 是否有货 数量
10;mM;*;1 mL in DMSO ￥5460 In-stock
5 mg ￥4500 In-stock
10 mg ￥6500 In-stock
50 mg ￥19500 In-stock
100 mg ; 询价 ;
200 mg ; 询价 ;

* Please select Quantity before adding items.

Z-WEHD-FMK 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Metabolism/Protease Compound Library
  • Anti-Cancer Compound Library
  • Pyroptosis Compound Library
  • Angiogenesis Related Compound Library
  • Peptide Library

生物活性

Z-WEHD-FMK is a potent, cell-permeable and irreversible caspase-1/5 inhibitor. Z-WEHD-FMK also exhibits a robust inhibitory effect on cathepsin B activity (IC50=6 μM). Z-WEHD-FMK can be used to investigate cells for evidence of apoptosis[1][2][4].

IC50 Target[1][2]

Caspase-1

;

体外研究
(In Vitro)

Z-WEHD-FMK (80 μM; 9 hours) elicits a near-complete blockage of C. trachomatis-induced cleavage of golgin-84 and increases GM130 expression in cells[1].
Z-WEHD-FMK (30 min before being exposed to E. piscicida) effectively inhibits 0909I E. piscicida induced ZF4 cells cytotoxicity and pyroptotic morphology. And in addition, it also inhibits the cytotoxicity induced by cytosolic LPS delivery[2].
Z-WEHD-FMK (20 μM;18-24 hours following Cr3+,Ni2+, and Co2+) significantly induces a decrease of 76% to 86% in IL-1β release with 200 to 400 ppm Cr3+, it also induces a decrease of 35% to 45% with 48 ppm Ni2+ or higher, Finally, this caspase-1 inhibitor induced a decrease with 6 ppm Co2+, down to a level below the detection threshold, and a decrease of 40% to 48% with 12 to 24 ppm Co2+ in bone marrow-derived macrophages (BMDM)[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: C. trachomatis– or mock-infected HeLa cells
Concentration: 80 μM
Incubation Time: 9 hours
Result: Increased golgin-84 and GM130 expression.

Cell Viability Assay[2]

Cell Line: Mycoplasma free-ZF4 cells
Concentration:
Incubation Time: 30 min before being exposed to E. piscicida
Result: Inhibited ZF4 cells cytotoxicity and pyroptotic morphology.

分子量

763.77

Formula

C37H42FN7O10
CAS 号

210345-00-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -80deg;C 2 years
-20deg;C 1 year
In solvent -80deg;C 6 months
-20deg;C 1 month
溶解性数据
In Vitro:;

DMSO : 100 mg/mL (130.93 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.3093 mL 6.5465 mL 13.0929 mL
5 mM 0.2619 mL 1.3093 mL 2.6186 mL
10 mM 0.1309 mL 0.6546 mL 1.3093 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂：;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.5 mg/mL (3.27 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.27 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂：;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (3.27 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.27 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂：;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (3.27 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.27 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献

  • [1]. Kamada S, et al. Caspase-4 and caspase-5, members of the ICE/CED-3 family of cysteine proteases, are CrmA-inhibitable proteases.Cell Death Differ. 1997 Aug;4(6):473-8.

    [2]. Yang D, et al. Sensing of cytosolic LPS through caspy2 pyrin domain mediates noncanonical inflammasome activation in zebrafish.Nat Commun. 2018 Aug 3;9(1):3052.

    [3]. Ferko MA, et al. Effects of metal ions on caspase-1 activation and interleukin-1β release in murine bone marrow-derived macrophages.PLoS One. 2018 Aug 23;13(8):e0199936.

    [4]. Newman ZL, et al. CA-074Me protection against anthrax lethal toxin.Infect Immun. 2009 Oct;77(10):4327-36.

荧光染料FITC-C6-DEVD-FMK

发表于由

荧光染料Dye Reagents FITC-C6-DEVD-FMK;

FITC-C6-DEVD-FMK 是一种 Caspase-3 荧光标记抑制剂。可用于检测哺乳动物细胞凋亡中的活性 caspase-3。Z-DEVD-FMK 是一种特异性 caspase-3 抑制剂。

FITC-C6-DEVD-FMK

FITC-C6-DEVD-FMK Chemical Structure

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

FITC-C6-DEVD-FMK, a fluorescently labeled caspase-3 inhibitor, can be used for detection of active caspase-3 in mammalian cells undergoing apoptosis. FITC-C6-DEVD-FMK provides a convenient means for sensitive detection of activated caspase-3 in living cells. Z-DEVD-FMK is a specific caspase-3 inhibitor[1].

分子量

994.99

Formula

C46H51FN6O16S
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Kanthasamy AG, et al. A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase C delta (PKCdelta) protects against dopaminergic neuronal degeneration in Parkinson’s disease models. Free Radic Biol Med. 2006 Nov

Z-YVAD-FMK

发表于由

Z-YVAD-FMK; 纯度: ge;98.0%

Z-YVAD-FMK 是一种具有细胞通透性 caspase-1 和 caspase-4 抑制剂，具有抗炎和抗肿瘤活性。

Z-YVAD-FMKamp;;

Z-YVAD-FMK Chemical Structure

CAS No. : 210344-97-1

规格 价格 是否有货 数量
10;mM;*;1 mL in DMSO ￥6940 In-stock
1 mg ￥2200 In-stock
5 mg ￥5000 In-stock
10 mg ￥8200 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Z-YVAD-FMK 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

Z-YVAD-FMK is a cell-permeable caspase-1 and -4 inhibitor with anti-inflammatory and anti-tumor activities[1].

IC50 Target

Caspase

;

体外研究
(In Vitro)

Z-YVAD-FMK (100 μM; 24 hours) significantly downregulated the growth inhibition induced by butyrate in Caco-2 cells[1].
Z-YVAD-FMK (20 μM; pre 1 hour; 24 hours) attenuates the apoptotic induction of III-10 on both HepG2 and BEL-7402 cells, the apoptotic rate of -10 on HepG2 cells is reduced by Z-VAD-FMK from 19.88% to 8.34%, while that on BEL-7402 cells is reduced from 17.56% to 11.98%[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Caco-2 cells
Concentration: 0-100 μM
Incubation Time: 24 hours
Result: Inhibited Caco-2 cells growth.

Apoptosis Analysis[1]

Cell Line: BEL-7402 and HepG2 cells
Concentration: 20 μM
Incubation Time: Pre 1 hour; 24 hours
Result: Induced a caspase-dependent apoptosis in cells.

分子量

630.66

Formula

C31H39FN4O9
CAS 号

210344-97-1
Sequence

Z-Tyr-Val-Ala-Asp-FMK
Sequence Shortening

Z-YVAD-FMK
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -80deg;C 2 years
-20deg;C 1 year
In solvent -80deg;C 6 months
-20deg;C 1 month
溶解性数据
In Vitro:;

DMSO : 125 mg/mL (198.21 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.5856 mL 7.9282 mL 15.8564 mL
5 mM 0.3171 mL 1.5856 mL 3.1713 mL
10 mM 0.1586 mL 0.7928 mL 1.5856 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂：;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.08 mg/mL (3.30 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.30 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂：;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (3.30 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.30 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂：;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.08 mg/mL (3.30 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.30 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献

  • [1]. Li H1,et al.Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release.J Immunol. 2007 Apr 15;178(8):5271-6.

    [2]. Avivi-Green C, et al. Different molecular events account for butyrate-induced apoptosis in two human colon cancer cell lines.J Nutr. 2002 Jul;132(7):1812-8.

荧光染料FITC-C6-LEHD-FMK

发表于由

荧光染料Dye Reagents FITC-C6-LEHD-FMK;

FITC-C6-LEHD-FMK 是一种 caspase-9 荧光标记抑制剂。可用于检测哺乳动物细胞凋亡中的活性 caspase-9。Z-DEVD-FMK 是一种特异性 caspase-9 抑制剂。

FITC-C6-LEHD-FMK

FITC-C6-LEHD-FMK Chemical Structure

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

FITC-C6-LEHD-FMK, a fluorescently labeled caspase-9 inhibitor, can be used for detection of active caspase-9 in mammalian cells undergoing apoptosis. FITC-C6-DEVD-FMK provides a convenient means for sensitive detection of activated caspase-9 in living cells. Z-LEHD-FMK is a specific caspase-9 inhibitor[1].

分子量

1031.07

Formula

C49H55FN8O14S
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Ozoren N, et, al. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2000 Nov 15; 60(22): 6259-65.